Comments are off

Cynvenio offers cfDNA purification upgrade

Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multitemplate analysis LiquidBiopsy platform. When coupled with Thermo Fisher Scientific’s Ion Torrent next-generation sequencing systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw. The Concordia option, which consists...
Learn More
Comments are off

Oracle offers precision medicine software

Oracle Health Sciences announced Oracle Healthcare Precision Medicine, software that connects genetic testing, report generation, and clinical care decision-making. Researchers and molecular pathologists face challenges in isolating clinically actionable information and creating individual diagnostic reports. Lack of traceability, scalability, data privacy/security, siloed tools, disparate terminologies, and varied workflows all contribute to their inability to collaborate...
Learn More
Comments are off

TST often misses TB in pregnant HIV+ women

New research finds that the most commonly used test for tuberculosis fails to accurately diagnose TB in up to 50 percent of pregnant women who are HIV positive. “The World Health Organization and many governments endorse the TST [tuberculin skin test] because it is a cheap and ubiquitous test,” lead study author Jyoti Mathad, MD,...
Learn More
Comments are off

Direct patient access to routine tests on rise

Revenues for routine direct-to-consumer laboratory tests were estimated to be worth $33.1 million in 2015, according to Kalorama Information. The market research firm said that routine DTC laboratory testing is expected to grow by an average 30 percent annually over the next five years. The aging population, uninsured patients, disease monitoring, and treatment monitoring will...
Learn More
Comments are off

Younger age linked to targetable genotypes in NSCLC

Patients younger than 50 diagnosed with non-small cell lung cancer have a higher likelihood of having a targetable genomic alteration for which therapies exist, says a study of more than 2,000 patients (Sacher AG, et al. JAMA Oncol. Published online ahead of print Dec. 17, 2015. doi:10.1001/jamaoncol.2015.4482). Geoffrey R. Oxnard, MD, of the Dana-Farber Cancer...
Learn More
Comments are off

FDA clears IL’s hemostasis testing systems

Bedford, Mass.-based Instrumentation Laboratory has received 510(k) clearance of their latest innovation, the ACL TOP Family 50 Series Hemostasis Testing Systems. The systems are designed for mid- to-high-volume clinical laboratories, including those using lab automation tracks. Commercialization in the U.S. will commence in 2016. The ACL TOP Family 50 Series systems have automated preanalytical sample...
Learn More
Comments are off

Kaiser to acquire Group Health

Kaiser Permanente and Group Health Cooperative have signed a definitive agreement for Kaiser Permanente to acquire Seattle-based Group Health. The combination will advance the growth of the integrated model for health care and coverage together and expand Kaiser Permanente’s reach, adding nearly 590,000 members. “This agreement is a natural extension of our long, successful working...
Learn More
Comments are off

NeoGenomics offers two new cfDNA tests

NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies. The NeoLab Solid Tumor Monitor is designed to quantify and track genomic...
Learn More
Comments are off

Swift to use Horizon NGS reference standards

Swift Biosciences will incorporate Horizon Discovery Group‘s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.  The Accel-Amplicon 56G Oncology Panel is a single tube assay that offers comprehensive and hotspot coverage of 56 clinically relevant oncology-related genes, using a 263-amplicon design to generate multiplex libraries...
Learn More
Comments are off

Arkray wins 3-year GPO deal for urinalysis

Arkray has been awarded a three-year agreement for automated urinalysis with Novation, a group purchasing organization. Under this agreement, organizations served by Novation—which includes members and affiliates of VHA, UHC, Children’s Hospital Association, and Provista—will have access to reduced costs and improved terms and conditions for the Aution Hybrid AU-4050 urine chemistry and sediment analyzer, Aution Max...
Learn More